2019
DOI: 10.1001/amajethics.2019.844
|View full text |Cite
|
Sign up to set email alerts
|

How Should We Determine the Value of CAR T-Cell Therapy?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…DAF considerations : With higher payer willingness to pay thresholds comes the possibility that developers will be motivated to inflate the price of GTs to meet the ICER threshold ( 52 , 53 ), in other words, the developers will charge the price as high as the payer are able to endure ( 26 ). It is unlikely that payers will accept innovative value-pricing methods, considering that they must be implemented with a radical modification of current policy.…”
Section: Economic Analysismentioning
confidence: 99%
“…DAF considerations : With higher payer willingness to pay thresholds comes the possibility that developers will be motivated to inflate the price of GTs to meet the ICER threshold ( 52 , 53 ), in other words, the developers will charge the price as high as the payer are able to endure ( 26 ). It is unlikely that payers will accept innovative value-pricing methods, considering that they must be implemented with a radical modification of current policy.…”
Section: Economic Analysismentioning
confidence: 99%
“…To date, scarce research has quantified real costs attributable to CAR T-cell therapy, which is crucial in drug reimbursement discussion between health players. Country-specific economic evaluations are necessary to determine whether and how to offer patients these highly personalized forms of immunotherapy [11,[20][21][22][23][24].…”
Section: Introductionmentioning
confidence: 99%